Coherus BioSciences Company Profile (NASDAQ:CHRS)

About Coherus BioSciences

Coherus BioSciences logoCoherus BioSciences, Inc. is a late-stage clinical biologics platform company. The Company is focused on the global biosimilar market. The Company operates through developing and commercializing biosimilar products segment. Its business is organized around therapeutic franchises, including Oncology biosimilar candidates pegfilgrastim (Neulasta), in late clinical-stage, and bevacizumab (Avastin), in preclinical-stage; Immunology (Anti-TNF) biosimilar candidates, etanercept (Enbrel) and adalimumab (Humira), which are both in late clinical-stage; Ophthalmology biosimilar candidate ranibizumab (Lucentis) in preclinical stage, and Multiple sclerosis small molecule therapeutic candidate, CHS-131 (formerly INT-131), in Phase II proof-of-concept trial. Its long-acting granulocyte colony-stimulating factor (G-CSF) product candidate, CHS-1701, is a pegfilgrastim (Neulasta) biosimilar. Its clinical-stage pipeline consists of two anti-Tumor Necrosis Factors (anti-TNFs).

Industry, Sector and Symbol:
  • Sector: Medical
  • Industry: Biotechnology
  • Sub-Industry: N/A
  • Exchange: NASDAQ
  • Symbol: CHRS
  • CUSIP:
Key Metrics:
  • Previous Close: $22.50
  • 50 Day Moving Average: $26.25
  • 200 Day Moving Average: $28.09
  • 52-Week Range: $13.10 - $31.98
  • Trailing P/E Ratio: N/A
  • Foreward P/E Ratio: -5.06
  • P/E Growth: 0.00
  • Market Cap: $1.00B
  • Outstanding Shares: 43,652,000
  • Beta: 4.82
Profitability:
  • Net Margins: -52.04%
  • Return on Assets: -47.08%
Debt:
  • Debt-to-Equity Ratio: 3.15%
  • Current Ratio: 3.04%
  • Quick Ratio: 3.04%
Additional Links:
Companies Related to Coherus BioSciences:

Analyst Ratings

Consensus Ratings for Coherus BioSciences (NASDAQ:CHRS) (?)
Ratings Breakdown: 7 Buy Ratings
Consensus Rating:Buy (Score: 3.00)
Consensus Price Target: $39.71 (74.95% upside)

Analysts' Ratings History for Coherus BioSciences (NASDAQ:CHRS)
Show:
DateFirmActionRatingPrice TargetDetails
2/1/2017Robert W. BairdReiterated RatingOutperform$40.00View Rating Details
11/25/2016Standpoint ResearchInitiated CoverageBuy$40.00View Rating Details
11/10/2016Maxim GroupReiterated RatingBuyView Rating Details
11/7/2016Citigroup Inc.Reiterated RatingBuy$36.00View Rating Details
10/4/2016Barclays PLCReiterated RatingOverweight$46.00View Rating Details
9/28/2016Credit Suisse GroupReiterated RatingBuy$38.00View Rating Details
3/1/2016J P Morgan Chase & CoLower Price TargetOverweight$37.00 -> $35.00View Rating Details
(Data available from 2/22/2015 forward)

Earnings

Earnings History for Coherus BioSciences (NASDAQ:CHRS)
DateQuarterConsensus EstimateActual EPSRevenue EstimateActual RevenueRelease LinkConference CallDetails
2/27/2017        
11/9/2016Q3 2016($1.56)$1.67$7.20 million$162.80 millionViewListenView Earnings Details
8/9/2016Q2($1.32)($1.72)$6.87 million$14.07 millionViewListenView Earnings Details
5/9/2016Q1($1.42)($1.67)ViewListenView Earnings Details
2/29/2016Q4($1.74)($1.35)ViewListenView Earnings Details
11/9/2015Q3($1.86)$16.10 million$7.20 millionViewListenView Earnings Details
8/10/2015Q215($1.56)$488.15 millionViewListenView Earnings Details
5/11/2015Q115($1.22)$488.15 millionViewListenView Earnings Details
3/23/2015Q414($0.46)($1.47)$6.50 millionViewListenView Earnings Details
12/15/2014Q212($1.79)$16.10 millionViewN/AView Earnings Details
3/27/2012($0.02)($0.06)ViewN/AView Earnings Details
12/1/2011($0.09)($0.08)ViewN/AView Earnings Details
9/1/2011$0.01($0.01)ViewN/AView Earnings Details
6/2/2011$0.12$0.17ViewN/AView Earnings Details
3/24/2011($0.19)($0.08)ViewN/AView Earnings Details
(Data available from 1/1/2011 forward)

Estimates

Earnings Estimates for Coherus BioSciences (NASDAQ:CHRS)
Current Year EPS Consensus Estimate: $-3.19 EPS
Next Year EPS Consensus Estimate: $-4.49 EPS

Dividends

Dividend History for Coherus BioSciences (NASDAQ:CHRS)
No dividend announcements for this company have been tracked by MarketBeat.com

Insider Trades

Insider Trading History for Coherus BioSciences (NASDAQ:CHRS)
Insider Ownership Percentage: 32.88%
Institutional Ownership Percentage: 64.52%
Transaction DateInsider NameTitleBuy/SellNumber of SharesAverage Share PriceTotal TransactionDetails
1/25/2017Jean-Frederic ViretCFOSell3,900$27.00$105,300.00View SEC Filing  
12/16/2016Jean-Frederic ViretCFOSell3,900$28.30$110,370.00View SEC Filing  
12/8/2016Mats WahlstromDirectorSell53,583$27.52$1,474,604.16View SEC Filing  
12/1/2016Alan C HermanInsiderSell11,333$27.40$310,524.20View SEC Filing  
10/21/2016Jean-Frederic ViretCFOSell3,900$30.62$119,418.00View SEC Filing  
10/3/2016Alan C HermanInsiderSell11,333$25.69$291,144.77View SEC Filing  
9/26/2016Jean-Frederic ViretCFOSell3,900$29.88$116,532.00View SEC Filing  
9/21/2016Dennis M LanfearInsiderSell4,060$31.75$128,905.00View SEC Filing  
9/16/2016Dennis M LanfearInsiderSell2,900$31.79$92,191.00View SEC Filing  
8/8/2016Fmr LlcInsiderSell100,000$29.86$2,986,000.00View SEC Filing  
8/5/2016Fmr LlcInsiderSell48,600$28.48$1,384,128.00View SEC Filing  
8/1/2016Alan C HermanInsiderSell11,333$25.54$289,444.82View SEC Filing  
7/21/2016Peter K WatlerInsiderSell3,991$26.13$104,284.83View SEC Filing  
7/20/2016Peter K WatlerInsiderSell73,741$25.02$1,844,999.82View SEC Filing  
7/11/2016Peter K WatlerInsiderSell43,495$20.02$870,769.90View SEC Filing  
7/1/2016Alan C HermanInsiderSell4,250$16.89$71,782.50View SEC Filing  
6/1/2016Alan C HermanInsiderSell4,250$18.67$79,347.50View SEC Filing  
5/17/2016Peter K WatlerInsiderSell12,000$20.00$240,000.00View SEC Filing  
5/2/2016Alan C HermanInsiderSell4,250$19.20$81,600.00View SEC Filing  
2/5/2016Alan C HermanInsiderSell2,000$15.02$30,040.00View SEC Filing  
12/1/2015Alan C. HermaninsiderSell11,333$29.49$334,210.17View SEC Filing  
11/13/2015Christos RichardsDirectorSell15,000$27.49$412,350.00View SEC Filing  
11/2/2015Alan C. HermaninsiderSell18,416$28.71$528,723.36View SEC Filing  
10/1/2015Alan C. HermaninsiderSell4,250$18.98$80,665.00View SEC Filing  
9/1/2015Alan C. HermaninsiderSell11,333$27.39$310,410.87View SEC Filing  
8/18/2015Mats WahlstromDirectorSell6,373$33.50$213,495.50View SEC Filing  
8/17/2015Mats WahlstromDirectorSell8,028$33.91$272,229.48View SEC Filing  
8/14/2015Mats WahlstromDirectorSell116,554$34.24$3,990,808.96View SEC Filing  
6/15/2015August J TroendleDirectorSell250,000$26.68$6,670,000.00View SEC Filing  
11/12/2014Eli & Co LillyInsiderBuy164,963$13.50$2,227,000.50View SEC Filing  
(Data available from 1/1/2013 forward)

Headlines

Latest Headlines for Coherus BioSciences (NASDAQ:CHRS)
DateHeadline
globenewswire.com logoCoherus BioSciences Announces New Employment Inducement Grants - GlobeNewswire (press release) (NASDAQ:CHRS)
globenewswire.com - February 18 at 4:08 PM
finance.yahoo.com logoCoherus BioSciences Announces New Employment Inducement Grants (NASDAQ:CHRS)
finance.yahoo.com - February 17 at 5:54 PM
News IconChecking the Numbers on Coherus Biosciences, Inc. (NASDAQ:CHRS) - Midway Monitor (NASDAQ:CHRS)
midwaymonitor.com - February 14 at 10:07 PM
marketexclusive.com logoCOHERUS BIOSCIENCES, INC. (NASDAQ:CHRS) Files An 8-K Entry into a Material Definitive Agreement (NASDAQ:CHRS)
marketexclusive.com - February 14 at 5:05 PM
biz.yahoo.com logoCOHERUS BIOSCIENCES, INC. Files SEC form 8-K, Entry into a Material Definitive Agreement, Other Events, Financial Sta (NASDAQ:CHRS)
biz.yahoo.com - February 13 at 9:55 PM
us.rd.yahoo.com logo8:31 am Coherus BioSciences prices underwritten public offering of 5,154,640 shares of its common stock at a price to the public of $24.25 per share (NASDAQ:CHRS)
us.rd.yahoo.com - February 10 at 2:40 AM
nasdaq.com logoCommit To Purchase Coherus BioSciences At $17.50, Earn 15.3% Annualized Using Options (NASDAQ:CHRS)
www.nasdaq.com - February 9 at 4:38 PM
streetinsider.com logoCoherus BioSciences (CHRS) Commences $125M Offering of ... - StreetInsider.com (NASDAQ:CHRS)
www.streetinsider.com - February 9 at 2:38 AM
marketexclusive.com logoCoherus Biosciences Inc (NASDAQ:CHRS) Could Be A Discount Entry On The Pullback (NASDAQ:CHRS)
marketexclusive.com - February 8 at 4:34 PM
baystreet.ca logoCoherus Biosciences (CHRS) Tumbles on Stock Offering (NASDAQ:CHRS)
www.baystreet.ca - February 8 at 4:34 PM
nasdaq.com logoRSI Alert: Coherus BioSciences (CHRS) Now Oversold (NASDAQ:CHRS)
www.nasdaq.com - February 8 at 4:34 PM
us.rd.yahoo.com logoCoherus Prices Public Offering of Common Stock (NASDAQ:CHRS)
us.rd.yahoo.com - February 8 at 4:34 PM
insidermonkey.com logoCoherus Biosciences Inc (CHRS) Could Be A Discount Entry On The Pullback (NASDAQ:CHRS)
www.insidermonkey.com - February 8 at 4:34 PM
fool.com logoWhy Coherus Biosciences Is Falling Today (NASDAQ:CHRS)
www.fool.com - February 8 at 4:34 PM
streetinsider.com logoCoherus BioSciences (CHRS) Commences $125M Offering of Common Stock (NASDAQ:CHRS)
www.streetinsider.com - February 7 at 5:22 PM
finance.yahoo.com logoCoherus Announces Proposed Public Offering of Common Stock (NASDAQ:CHRS)
finance.yahoo.com - February 7 at 5:22 PM
streetinsider.com logoCoherus BioSciences (CHRS) Files Four Petitions for IPR Review Against AbbVie's HUMIRA '619 Patent - StreetInsider.com (NASDAQ:CHRS)
www.streetinsider.com - February 1 at 6:36 AM
us.rd.yahoo.com logoCoherus BioSciences Files Four Petitions for Inter Partes Review Against AbbVie’s HUMIRA® Formulation Patent 9,085,619 (NASDAQ:CHRS)
us.rd.yahoo.com - January 31 at 9:45 PM
News IconStock Spotlight: Looking at the Levels for Coherus Biosciences, Inc. (NASDAQ:CHRS) - The Tribune (NASDAQ:CHRS)
lakecitytribune.com - January 31 at 4:45 PM
capitalcube.com logoCoherus BioSciences, Inc. – Value Analysis (NASDAQ:CHRS) : January 27, 2017 (NASDAQ:CHRS)
www.capitalcube.com - January 27 at 5:39 PM
News IconEarnings in Full Force, Analysts Take Aim at Coherus BioSciences, Inc. (NASDAQ:CHRS) - Wall Street Beacon (NASDAQ:CHRS)
wsbeacon.com - January 26 at 10:15 PM
News IconRelative Strength Index Check on Coherus Biosciences Inc. (CHRS) - Market Point (NASDAQ:CHRS)
mtptnews.com - January 26 at 5:14 PM
capitalcube.com logoCoherus BioSciences, Inc. breached its 50 day moving average in a Bullish Manner : CHRS-US : January 26, 2017 (NASDAQ:CHRS)
www.capitalcube.com - January 26 at 5:14 PM
News IconStock to Watch: Coherus Biosciences, Inc. (NASDAQ:CHRS) - The Tribune (NASDAQ:CHRS)
lakecitytribune.com - January 24 at 9:51 PM
News IconVhcp Management LLC Position in Coherus Biosciences INC (CHRS) Decreased by $7.94 Million (NASDAQ:CHRS)
randolphguide.com - January 24 at 4:51 PM
News IconWill The Needle Move For Coherus BioSciences, Inc. (NASDAQ:CHRS) Shares This Earnings Season? - Wall Street Beacon (NASDAQ:CHRS)
wsbeacon.com - January 21 at 9:19 PM
News IconCoherus BioSciences Inc CHRS Pharmaceuticals Healthcare Deals and Alliances Profile Prices from USD $250 (NASDAQ:CHRS)
www.bioportfolio.com - January 21 at 4:18 PM
bizjournals.com logoSpeed of Peninsula biotech's potential blockbuster drug rests with Supreme Court - San Francisco Business Times (NASDAQ:CHRS)
www.bizjournals.com - January 20 at 10:28 PM
News IconRSI Review on Shares of Coherus Biosciences Inc. (CHRS) - Sherwood Daily (NASDAQ:CHRS)
sherwooddaily.com - January 20 at 10:28 PM
News IconGearing Up For a Bull Run? Analysts Weigh in on Coherus BioSciences, Inc. (NASDAQ:CHRS) - Wall Street Beacon (NASDAQ:CHRS)
wsbeacon.com - January 19 at 5:29 PM
capitalcube.com logoETFs with exposure to Coherus BioSciences, Inc. : January 19, 2017 (NASDAQ:CHRS)
www.capitalcube.com - January 19 at 5:29 PM
News IconCan This Stock Hit on All Cylinders And Achieve Projections: Coherus Biosciences, Inc. (NASDAQ:CHRS) - Prospect Journal (NASDAQ:CHRS)
prospectjournal.com - January 17 at 9:06 AM
News IconAverage Directional Index in Review for Coherus Biosciences Inc. (CHRS) - Springdale Times (NASDAQ:CHRS)
springdaletimes.com - January 16 at 4:19 PM
realistinvestor.com logoCoherus BioSciences, Inc. (NASDAQ:CHRS) EPS Estimate At $-1.63 - RealistInvestor.com (NASDAQ:CHRS)
www.realistinvestor.com - January 13 at 5:00 PM
finance.yahoo.com logo8:46 am Coherus BioSciences announces 'positive' topline 24-week treatment phase 3 results for CHS-1420 in patients with psoriasis (NASDAQ:CHRS)
finance.yahoo.com - January 11 at 3:07 AM
streetinsider.com logoCoherus BioSciences (CHRS) Reports 24-Week Data from Phase Three Study of CHS-1420 to Treat Psoriasis (NASDAQ:CHRS)
www.streetinsider.com - January 10 at 10:04 PM
nasdaq.com logoCoherus BioSciences Announces Positive Topline 24-Week Treatment Phase Three Results for CHS-1420 (NASDAQ:CHRS)
www.nasdaq.com - January 10 at 10:04 PM
capitalcube.com logoCoherus BioSciences, Inc. breached its 50 day moving average in a Bearish Manner : CHRS-US : January 10, 2017 (NASDAQ:CHRS)
us.rd.yahoo.com - January 10 at 10:04 PM
us.rd.yahoo.com logoCoherus BioSciences Announces Positive Topline 24-Week Treatment Phase Three Results for CHS-1420 (HUMIRA® Biosimilar Candidate) in Patients with Psoriasis (NASDAQ:CHRS)
us.rd.yahoo.com - January 10 at 10:04 PM
streetinsider.com logoCoherus BioSciences (CHRS) Reports 24-Week Data from Phase Three Study of CHS-1420 to Treat Psoriasis - StreetInsider.com (NASDAQ:CHRS)
www.streetinsider.com - January 10 at 5:00 PM
realistinvestor.com logoCoherus BioSciences, Inc. (NASDAQ:CHRS) Is Expected To Post ... - RealistInvestor.com (NASDAQ:CHRS)
www.realistinvestor.com - January 6 at 2:48 AM
globenewswire.com logoCoherus BioSciences Management to Present at The 35th Annual J.P. Morgan Healthcare Conference - GlobeNewswire (press release) (NASDAQ:CHRS)
globenewswire.com - January 5 at 3:22 AM
finance.yahoo.com logoCoherus BioSciences Management to Present at The 35th Annual J.P. Morgan Healthcare Conference (NASDAQ:CHRS)
finance.yahoo.com - January 4 at 5:19 PM
News IconCoherus BioSciences Inc. (CHRS) Shares Active after Upgrade at ... - BNB Daily (blog) (NASDAQ:CHRS)
www.baseball-news-blog.com - January 3 at 6:01 PM
capitalcube.com logoCoherus BioSciences, Inc. breached its 50 day moving average in a Bullish Manner : CHRS-US : December 19, 2016 (NASDAQ:CHRS)
www.capitalcube.com - December 20 at 7:52 AM
News IconInvestor Circle: Watching the Numbers on Shares of Coherus Biosciences, Inc. (NASDAQ:CHRS) - Marion Business Daily (NASDAQ:CHRS)
marionbusinessdaily.com - December 13 at 9:59 PM
insidermonkey.com logoHedge Funds Are Betting On Coherus Biosciences Inc (CHRS ... - Insider Monkey (blog) (NASDAQ:CHRS)
www.insidermonkey.com - December 13 at 9:59 PM
insidermonkey.com logoHedge Funds Are Betting On Coherus Biosciences Inc (CHRS) (NASDAQ:CHRS)
www.insidermonkey.com - December 13 at 4:58 PM
News IconCCI Level Review on Coherus Biosciences Inc. (CHRS) - StockTalk Daily (NASDAQ:CHRS)
stocktalkdaily.com - December 13 at 6:46 AM
News IconValue Focus: Following the Numbers for Coherus Biosciences, Inc. (NASDAQ:CHRS) - The Business Journal (NASDAQ:CHRS)
belmontbusinessjournal.com - December 10 at 4:16 PM

Social

What is Coherus BioSciences' stock symbol?

Coherus BioSciences trades on the NASDAQ under the ticker symbol "CHRS."

Where is Coherus BioSciences' stock going? Where will Coherus BioSciences' stock price be in 2017?

7 equities research analysts have issued 1-year price objectives for Coherus BioSciences' stock. Their predictions range from $35.00 to $46.00. On average, they anticipate Coherus BioSciences' share price to reach $39.71 in the next twelve months.

When will Coherus BioSciences announce their earnings?

Coherus BioSciences is scheduled to release their next quarterly earnings announcement on Monday, February, 27th 2017.

Who owns Coherus BioSciences stock?

Coherus BioSciences' stock is owned by a variety of of institutional and retail investors. Top institutional shareholders include FMR LLC (15.00%), State Street Corp (2.18%), Orbimed Advisors LLC (1.95%), Highland Capital Management LP (0.82%), Brown Advisory Inc. (0.77%) and JHL Capital Group LLC (0.57%). Company insiders that own Coherus BioSciences stock include Alan C Herman, August J Troendle, Christos Richards, Dennis M Lanfear, Fmr Llc, Jean-Frederic Viret, Mats Wahlstrom and Peter K Watler.

Who sold Coherus BioSciences stock? Who is selling Coherus BioSciences stock?

Coherus BioSciences' stock was sold by a variety of institutional investors in the last quarter, including Turner Investments LLC, Highland Capital Management LP and Commerzbank Aktiengesellschaft FI. Company insiders that have sold Coherus BioSciences stock in the last year include Alan C Herman, Dennis M Lanfear, Fmr Llc, Jean-Frederic Viret, Mats Wahlstrom and Peter K Watler.

Who bought Coherus BioSciences stock? Who is buying Coherus BioSciences stock?

Coherus BioSciences' stock was acquired by a variety of institutional investors in the last quarter, including JHL Capital Group LLC, Orbimed Advisors LLC, State Street Corp, Two Sigma Investments LP, Thrivent Financial for Lutherans, FMR LLC, Russell Investments Group Ltd. and Marshall Wace LLP.

How do I buy Coherus BioSciences stock?

Shares of Coherus BioSciences can be purchased through any online brokerage account. Popular online brokerages include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

How much does a share of Coherus BioSciences stock cost?

One share of Coherus BioSciences stock can currently be purchased for approximately $22.70.

Coherus BioSciences (NASDAQ:CHRS) Chart for Wednesday, February, 22, 2017


Institutional Ownership Chart

Institutional Ownership by Quarter for Coherus BioSciences (NASDAQ:CHRS)

Earnings History Chart

Earnings by Quarter for Coherus BioSciences (NASDAQ:CHRS)

Dividend History Chart

Dividend Payments by Quarter for Coherus BioSciences (NASDAQ:CHRS)

Last Updated on 2/22/2017 by MarketBeat.com Staff